Piper Sandler reiterates an Overweight rating on Crispr Therapeutics (CRSP) with a $105 price target after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Casgevy for the treatment of transfusion-dependent beta thalassemia and sickle cell disease patients aged 12 and up. This sets up a likely European conditional approval by February 2024, the analyst tells investors in a research note. The firm says Crispr continues to advance gene edited CAR-T therapies for cancer and autoimmune disease, and Type 1 diabetes, as well as in vivo cardiovascular gene editing medicines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics call volume above normal and directionally bullish
- The biopharma stocks to own in 2024, according to Morgan Stanley
- Crispr Therapeutics price target raised by $4 at Morgan Stanley, here’s why
- CRISPR Therapeutics (NASDAQ:CRSP) Tanks after Analyst Downgrade
- Biotech Alert: Searches spiking for these stocks today